These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 25933393)

  • 21. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.
    Ungar B; Levy I; Yavne Y; Yavzori M; Picard O; Fudim E; Loebstein R; Chowers Y; Eliakim R; Kopylov U; Ben-Horin S
    Clin Gastroenterol Hepatol; 2016 Apr; 14(4):550-557.e2. PubMed ID: 26538204
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low muscle mass at initiation of anti-TNF therapy for inflammatory bowel disease is associated with early treatment failure: a retrospective analysis.
    Holt DQ; Varma P; Strauss BJG; Rajadurai AS; Moore GT
    Eur J Clin Nutr; 2017 Jun; 71(6):773-777. PubMed ID: 28225051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease.
    Okuyucu M; Avcioğlu U; Şenel T; Ustaoğlu M
    Medicine (Baltimore); 2022 Sep; 101(35):e30118. PubMed ID: 36107528
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association between thrombocytosis and iron deficiency anemia in inflammatory bowel disease.
    Voudoukis E; Karmiris K; Oustamanolakis P; Theodoropoulou A; Sfiridaki A; Paspatis GA; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1212-6. PubMed ID: 23839158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of inflammatory bowel disease patients treated with TNF-α inhibitors: two-year follow-up.
    Lehtola E; Haapamäki J; Färkkilä MA
    Scand J Gastroenterol; 2016 Dec; 51(12):1476-1481. PubMed ID: 27686143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement.
    Gisbert JP; Bermejo F; Pajares R; Pérez-Calle JL; Rodríguez M; Algaba A; Mancenido N; de la Morena F; Carneros JA; McNicholl AG; González-Lama Y; Maté J
    Inflamm Bowel Dis; 2009 Oct; 15(10):1485-91. PubMed ID: 19408339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
    Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
    J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-TNF-
    Shu W; Pang Z; Xu C; Lin J; Li G; Wu W; Sun S; Li J; Li X; Liu Z
    Mediators Inflamm; 2019; 2019():4038619. PubMed ID: 31814801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha in Very Early Onset Inflammatory Bowel Disease.
    Collen LV; Mitsialis V; Kim DY; Bresnahan M; Yang J; Tuthill M; Combs A; Barends J; Field M; Liu E; Bearup R; Okoroafor I; Klein C; Muise AM; Bousvaros A; Ouahed J; Snapper SB
    Inflamm Bowel Dis; 2024 Sep; 30(9):1443-1453. PubMed ID: 37847820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Negative Screening Does Not Rule Out the Risk of Tuberculosis in Patients with Inflammatory Bowel Disease Undergoing Anti-TNF Treatment: A Descriptive Study on the GETAID Cohort.
    Abitbol Y; Laharie D; Cosnes J; Allez M; Nancey S; Amiot A; Aubourg A; Fumery M; Altwegg R; Michetti P; Chanteloup E; Seksik P; Baudry C; Flamant M; Bouguen G; Stefanescu C; Bourrier A; Bommelaer G; Dib N; Bigard MA; Viennot S; Hébuterne X; Gornet JM; Marteau P; Bouhnik Y; Abitbol V; Nahon S;
    J Crohns Colitis; 2016 Oct; 10(10):1179-85. PubMed ID: 27402916
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
    Karmiris K; Bossuyt P; Sorrentino D; Moreels T; Scarcelli A; Legido J; Dotan I; Naismith GD; Jussila A; Preiss JC; Kruis W; Li AC; Bouguen G; Yanai H; Steinwurz F; Katsanos KH; Subramaniam K; Tarabar D; Zaganas IV; Ben-Horin S;
    J Crohns Colitis; 2015 May; 9(5):382-9. PubMed ID: 25740813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of axial spondyloarthritis after one year of anti-tumor necrosis factor therapy among patients with inflammatory bowel diseases.
    Dalal RS; Ermann J; Carlin A; Mitri J; Allegretti JR
    Clin Rheumatol; 2023 Nov; 42(11):3001-3006. PubMed ID: 37428414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of psoriasis in IBD patients under TNF-antagonist therapy is associated neither with anti-TNF-antagonist antibodies nor trough levels.
    Protic M; Schoepfer A; Yawalkar N; Vavricka S; Seibold F
    Scand J Gastroenterol; 2016 Dec; 51(12):1482-1488. PubMed ID: 27534974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relapse rate following withdrawal of anti-TNF therapy in patients with inflammatory bowel disease: A real-life cohort from northern India.
    Sahu P; Vuyyuru SK; Kante B; Agarwal A; Sharma R; Das P; Panwar R; Jain S; Bopanna S; Makharia G; Kedia S; Ahuja V
    Indian J Gastroenterol; 2020 Aug; 39(4):388-397. PubMed ID: 32880844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors Associated with Discontinuation of Anti-TNF Inhibitors Among Persons with IBD: A Population-Based Analysis.
    Targownik LE; Tennakoon A; Leung S; Lix LM; Nugent Z; Singh H; Bernstein CN
    Inflamm Bowel Dis; 2017 Mar; 23(3):409-420. PubMed ID: 28221250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous Iron Replacement Improves Quality of Life in Hypoferritinemic Inflammatory Bowel Disease Patients with and without Anemia.
    Eliadou E; Kini G; Huang J; Champion A; Inns SJ
    Dig Dis; 2017; 35(5):444-448. PubMed ID: 28334707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Slow hematological recovery in children with IBD-associated anemia in cases of "expectant management".
    Pels LP; Van de Vijver E; Waalkens HJ; Uitentuis J; JGonera-de ong G; van Overbeek LA; Norbruis OF; Rings EH; van Rheenen PF
    J Pediatr Gastroenterol Nutr; 2010 Dec; 51(6):708-13. PubMed ID: 20683207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Adalimumab Levels Predict Successful Remission and Safe Deintensification in Inflammatory Bowel Disease Patients in Clinical Practice.
    Aguas Peris M; Bosó V; Navarro B; Marqués-Miñana MR; Bastida G; Beltrán B; Iborra M; Sáez-González E; Monte-Boquet E; Poveda-Andrés JL; Nos P
    Inflamm Bowel Dis; 2017 Aug; 23(8):1454-1460. PubMed ID: 28708805
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.